These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36805862)

  • 1. Naltrexone-bupropion combinations do not affect cocaine self-administration in humans.
    Regnier SD; Stoops WW; Lile JA; Alcorn JL; Bolin BL; Reynolds AR; Hays LR; Rayapati AO; Rush CR
    Pharmacol Biochem Behav; 2023 Mar; 224():173526. PubMed ID: 36805862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine.
    Stoops WW; Pike E; Hays LR; Glaser PE; Rush CR
    Pharmacol Biochem Behav; 2015 Feb; 129():45-50. PubMed ID: 25459104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topiramate-phentermine combinations reduce cocaine self-administration in humans.
    Rush CR; Stoops WW; Lile JA; Alcorn JL; Bolin BL; Reynolds AR; Hays LR; Rayapati AO
    Drug Alcohol Depend; 2021 Jan; 218():108413. PubMed ID: 33290875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-administration of cocaine-heroin combinations by rhesus monkeys: antagonism by naltrexone.
    Rowlett JK; Wilcox KM; Woolverton WL
    J Pharmacol Exp Ther; 1998 Jul; 286(1):61-9. PubMed ID: 9655842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers.
    Oliveto A; McCance-Katz FE; Singha A; Petrakis I; Hameedi F; Kosten TR
    Drug Alcohol Depend; 2001 Jul; 63(2):155-67. PubMed ID: 11376920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of eticlopride and naltrexone on responding maintained by food, cocaine, heroin and cocaine/heroin combinations in rats.
    Hemby SE; Smith JE; Dworkin SI
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1247-58. PubMed ID: 8667185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with naltrexone and bupropion for obesity.
    Billes SK; Greenway FL
    Expert Opin Pharmacother; 2011 Aug; 12(11):1813-26. PubMed ID: 21689063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss.
    Prescrire Int; 2015 Oct; 24(164):229-33. PubMed ID: 26594724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
    Grilo CM; Lydecker JA; Morgan PT; Gueorguieva R
    Clin Ther; 2021 Jan; 43(1):112-122.e1. PubMed ID: 33218742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naltrexone-buprenorphine interactions: effects on cocaine self-administration.
    Mello NK; Lukas SE; Mendelson JH; Drieze J
    Neuropsychopharmacology; 1993 Nov; 9(3):211-24. PubMed ID: 8280345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bupropion and Naltrexone in Methamphetamine Use Disorder.
    Trivedi MH; Walker R; Ling W; Dela Cruz A; Sharma G; Carmody T; Ghitza UE; Wahle A; Kim M; Shores-Wilson K; Sparenborg S; Coffin P; Schmitz J; Wiest K; Bart G; Sonne SC; Wakhlu S; Rush AJ; Nunes EV; Shoptaw S
    N Engl J Med; 2021 Jan; 384(2):140-153. PubMed ID: 33497547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
    Wadden TA; Foreyt JP; Foster GD; Hill JO; Klein S; O'Neil PM; Perri MG; Pi-Sunyer FX; Rock CL; Erickson JS; Maier HN; Kim DD; Dunayevich E
    Obesity (Silver Spring); 2011 Jan; 19(1):110-20. PubMed ID: 20559296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
    Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR
    JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update.
    Christou GA; Kiortsis DN
    Hormones (Athens); 2015; 14(3):370-5. PubMed ID: 26188223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
    Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.
    Mooney LJ; Hillhouse MP; Thomas C; Ang A; Sharma G; Terry G; Chang L; Walker R; Trivedi M; Croteau D; Sparenborg S; Ling W
    J Addict Med; 2016; 10(4):236-43. PubMed ID: 27379819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial.
    Grilo CM; Lydecker JA; Gueorguieva R
    Psychol Med; 2023 Dec; 53(16):7775-7784. PubMed ID: 37366017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.